What's Happening?
Bifrost Biosystems has announced a commercial supply agreement with Illumina to integrate Illumina's sequencing-by-synthesis (SBS) chemistry into Bifrost's optical pooled screening (OPS) platform. This platform is designed to link complex cellular phenotypes
to genetic perturbations efficiently and at scale. The agreement ensures Bifrost has access to high-performance sequencing chemistry, which will be included in their OPS optimized reagent kits. This development is a significant step towards the commercial deployment of Bifrost's technology, which is expected to be available in early 2027. The OPS platform aims to democratize high-content functional genomics by combining advanced imaging, microfluidics, and sequencing-based readouts.
Why It's Important?
The agreement between Bifrost Biosystems and Illumina is crucial for advancing the capabilities of functional genomics research. By securing reliable access to Illumina's sequencing chemistry, Bifrost can enhance its OPS platform, making it a more accessible and scalable tool for researchers. This could lead to significant advancements in understanding genetic diseases and developing new treatments. The collaboration also positions Bifrost to engage in early-access partnerships with leading research institutions and biotechnology companies, potentially accelerating innovation in the field.
What's Next?
Bifrost Biosystems is preparing for broader early-access deployments of its OPS platform to select research institutions and biotechnology companies. This move is expected to facilitate further validation and refinement of the technology, paving the way for its widespread adoption in the scientific community. The integration of Illumina's sequencing chemistry is anticipated to enhance the platform's performance, making it a valuable tool for researchers aiming to conduct high-throughput genetic screenings.
